Healwell AI Seeks to Bridge Valuation Chasm at Key Investor Conference

Healwell AI trades at a 25% discount despite record 2025 revenue of $103.8M and its first positive EBITDA. Management aims to convince investors at a key Toronto conference.

Despite posting record-breaking financial results, shares of healthcare AI company Healwell AI are trading at a steep discount. The stock, currently around 0.50 to 0.51 EUR, has fallen roughly 40% over the past year and sits about 25% below its 200-day moving average of 0.68 EUR. This disconnect sets the stage for a critical management presentation at the Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 21 and 22, 2026.

The company’s fundamental story appears robust. For fiscal year 2025, Healwell AI reported record revenue of $103.8 million, a staggering 427% year-over-year increase. Crucially, it also achieved its first full-year of positive adjusted EBITDA at $2.3 million. The recurring revenue stream from subscriptions and maintenance soared by 522% to $66.8 million, underscoring a successful pivot to a pure-play SaaS and AI provider in healthcare.

CEO James Lee and President Dr. Alexander Dobranowski will use the Toronto conference for one-on-one meetings with institutional investors. Their pitch will center on the firm’s strategic vision for AI-powered healthcare, which includes clinical decision support systems designed for early disease detection and improving clinic efficiency. The goal is to translate operational success into market confidence.

Further bolstering its credibility, Healwell AI has built what it calls a "scientific moat." By mid-March 2026, its proprietary DARWEN AI platform had been validated in 47 peer-reviewed publications across various disease areas. The company also launched the WELLTRUST platform in partnership with WELL Health Technologies, a tool aimed at helping pharmaceutical companies accelerate patient recruitment for clinical trials through AI-driven data management.

Operational momentum has continued into the new year. In early March 2026, Healwell AI secured a multi-year, multi-million dollar software contract with a U.S. Health Information Exchange. The deal involves its Orion Health and VeroSource divisions working to make patient data usable across hospitals and health authorities.

For 2026, management is targeting approximately 50% growth in its AI revenue and aims to achieve an adjusted EBITDA margin near 10% by year-end, focusing on global scaling and expanded sales channels. However, the market remains skeptical. The stock’s recent bounce from a February low of 0.37 EUR has pushed its Relative Strength Index (RSI) to 70, indicating short-term overbought conditions. Annualized volatility exceeding 85% highlights ongoing investor nervousness.

Analyst coverage suggests significant potential upside. TD Securities and Raymond James, which cover the stock, have issued price targets ranging from 1.75 to 2.50 Canadian dollars. The next major test for the company comes in mid-May 2026, when it is scheduled to report first-quarter 2026 results. The outcome of the Toronto investor talks will soon be reflected in order book activity, revealing whether Healwell AI can finally narrow the gap between its performance and its share price.